Clinical Trial

Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer

Study acronym: LuCAB
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated April 6, 2025 (before its estimated June 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
This clinical trial will evaluate the safety of Cabazitaxel in combination with 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-04-14; most recent amendment 2025-04-03.
Status change: Recruiting → Active, Not Recruiting 2025-04-03
Status change: Not Yet Recruiting → Recruiting 2022-07-20
Trial Details
NCT Number NCT05340374
Lead Sponsor Peter MacCallum Cancer Centre, Australia
Conditions Metastatic Castration-resistant Prostate Cancer, mCRPC
Enrollment 35 participants
Start Date 2022-07-14
Primary Completion 2026-06-20 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-04-06